GBM AGILE Leadership Council

 

David Arons, JD

Advocacy Partner, National Brain Tumor Society
President & Chief Executive Officer,
National Brain Tumor Society


Sujuan Ba, PhD
Advocacy Partner, Asian Fund for Cancer Research and National Foundation of Cancer Research
Chief Executive Officer,
National Foundation for Cancer Research
Founder & Chief Executive Officer,
Asian Fund for Cancer Research
Co-founder & Chief Executive Officer,
AIM-HI Accelerator Fund


Donald A. Berry, PhD
Lead Statistician
Professor, Department of Biostatistics,
The University of Texas MD Anderson Cancer Center
Adjunct Professor, Department of Department of Statistics,
Rice University
Founder & Senior Statistical Scientist,
Berry Consultants


Nicholas A. Blondin, MD
Co-PI, ADI-PEG 20
Assistant Professor, Clinical Neurology
Yale School of Medicine
Smilow Cancer Hospital and
Yale Comprehensive Cancer Center


Tim Cloughesy, MD
Global PI; Arm Selection Committee Member; Biomarker Committee Member
Chief Medical Officer and Board Member,
Global Coalition for Adaptive Research
Director, Neuro-Oncology Program
Professor, Neurology
University of California Los Angeles


Howard Colman, MD, PhD
Regional PI, U.S.; Co-PI, VT1021
Professor, Huntsman Cancer Institute and
Department of Neurosurgery, University of Utah


John de Groot, MD
Arm Selection Committee Member; Co-PI, VAL-083
Professor and Chief, Division of Neuro-Oncology,
Department of Neurosurgery,
University of California San Francisco


Macarena De la Fuente, MD
Co-PI, ADI-PEG 20
Associate Professor of Neuro-Oncology
Chief, Neuro-Oncology
Clinical Service Leader for Neuro-Oncology Service Line,
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine 


Benjamin Ellingson, PhD
Imaging Lead; Biomarker Committee Member
Director, UCLA Brain Tumor Imaging Laboratory (BTIL)
Co-Director of the Center for Computer Vision and Imaging Biomarkers
Member, UCLA Brain Tumor Program
Professor, Radiological Sciences, Psychiatry and Biobehavioral Sciences, Neurosurgery,
University of California Los Angeles


Hui Gan, MBBS, PhD
Regional PI, Australia
Clinical Research Lead, Olivia Newton-John Cancer Research Institute
Clinician Scientist, Tumour Targeting Laboratory
Co-Director, Centre for Research Excellence in Brain Cancer
Director, Cancer Clinical Trials Centre, Austin Health


Gary B. Gordon, MD, PhD
Biomarker Committee Member
Senior Medical Advisor and Board Member,
Global Coalition for Adaptive Research


Lance Kawaguchi
Advocacy partner, Cure Brain Cancer Foundation
Chief Executive Officer,
Cure Brain Cancer Foundation 


Mustafa Khasraw, MD
Biomarker Committee Member
Professor of Neurosurgery
Professor in Medicine
Deputy Director, Center for Cancer Immunotherapy,
Duke Cancer Institute


Andrew B. Lassman, MD
Arm Selection Committee Member; Co-PI, Regorafenib
Professor of Neurology and Associate Dean of Clinical Trials,
Columbia University Vagelos College of Physicians and Surgeons
Chief, Department of Neurology Division of Neuro-Oncology and
Associate Director for Clinical Trials,
Herbert Irving Comprehensive Cancer Center


Eudocia Q. Lee, MD, MPH
Co-PI, Paxalisib
Director of Clinical Research, Neuro-Oncology
Associate Professor of Neurology,
Harvard Medical School and Dana-Farber Cancer Institute


Michael Lim, MD
Arm Selection Committee Member; Co-PI, Troriluzole
Chair, Department of Neurosurgery,
Professor of Neurosurgery,
Stanford University
Member, NCI Brain Malignancy Steering Committee


Ingo K. Mellighoff, MD, FACP
Arm Selection Committee Co-Chair; Co-PI, Paxalisib
Chair, Department of Neurology; Chief, Brain Tumor Service
Evnin Family Chair in Neuro-Oncology
Memorial Sloan Kettering Cancer Center


Tom Mikkelsen, MD
Co-PI, VT1021
Medical Director, Precision Medicine Program & Clinical Trials
Henry Ford Cancer Institute


James Perry, MD, FRCPC
Regional PI, Canada; Co-PI, VAL-083
Affiliate scientist, Evaluative Clinical Sciences, Odette Cancer Research Program,
Sunnybrook Research Institute
Professor, Department of Medicine, Division of Neurology, University of Toronto
Tony Crolla Chair in Brain Tumour Research
Chairman, Canadian Brain Tumour Consortium


Erik P. Sulman, MD, PhD
Radiation Oncology Lead
Professor, Department of Radiation Oncology, NYU Grossman School of Medicine
Co-Director, Medical Scientist Training Program
Co-Director, Brain and Spine Tumor Center
Vice Chair for Research, Dept of Radiation Oncology
NYU Langone’s Perlmutter Cancer Center


Kirk Tanner, PhD
Arm Selection Committee Member
Chief Scientific Officer,
Senior Vice President, Brain Tumor Investment Fund
National Brain Tumor Society


Michael Weller, MD
Regional PI, Europe; Arm Selection Committee Member; Co-PI, Troriluzole
Chair, Department of Neurology,
Professor of Neurology
University Hospital Zurich


Patrick Y. Wen, MD
Arm Selection Committee Co-Chair; Arm Co-PI, Regorafenib
Director, Center for Neuro-Oncology,
Dana-Farber Cancer Institute
Professor of Neurology, Harvard Medical School


W.K. Alfred Yung, MD
Biomarker Committee Member
Professor, Neuro-Oncology,
The University of Texas MD Anderson Cancer Center
Co-chair, NCI Brain Malignancy Steering Committee

 

 


240 k

240,000 people worldwide are diagnosed with GBM each year

95 %

GBM kills 95% of patients within five years of diagnosis

64

Mean age at diagnosis is 64

Join in the Fight Against Brain Cancer